NASDAQ
PSTI

Pluristem Therapeutics Inc

Biotechnology
Healthcare

Prices are adjusted according to historical splits.

Pluristem Therapeutics Inc Stock Price

Vitals

Today's Low:
$
Today's High:
$
Open Price:
$
52W Low:
$2.82
52W High:
$13.29
Prev. Close:
$
Volume:

Company Statistics

Market Cap.:
$0.261 billion
Book Value:
2.201
Revenue TTM:
$0.000 billion
Operating Margin TTM:
-128156.52%
Gross Profit TTM:
$0.000 billion
Gross Profit TTM:
$0.000 billion
Profit Margin:
0%
Return on Assets TTM:
-38.05%
Return on Equity TTM:
-74.82%

Company Profile

Pluristem Therapeutics Inc had its IPO on 2003-06-30 under the ticker symbol PSTI.

The company operates in the Healthcare sector and Biotechnology industry. Pluristem Therapeutics Inc has a staff strength of 146 employees.

Stock update

Shares of Pluristem Therapeutics Inc opened at $0 at the start of the last trading session i.e. .

The stocks traded within a range of $0 - $0, and closed at $0.

This is a 0% increase from the previous day's closing price.

A total volume of 0 shares were traded at the close of the day’s session.

In the last one week, shares of Pluristem Therapeutics Inc have increased by 0%.

Pluristem Therapeutics Inc's Key Ratios

Pluristem Therapeutics Inc has a market cap of $0.261 billion, indicating a price to book ratio of 4.6098 and a price to sales ratio of 8006.8133.

In the last 12-months Pluristem Therapeutics Inc’s revenue was $0.000 billion with a gross profit of $0.000 billion and an EBITDA of $-0.034 billion. The EBITDA ratio measures Pluristem Therapeutics Inc's overall financial performance and is widely used to measure its profitability.

In the trailing 12-month period, Pluristem Therapeutics Inc’s operating margin was -128156.52% while its return on assets stood at -38.05% with a return of equity of -74.82%.

In Q2, Pluristem Therapeutics Inc’s quarterly earnings growth was a positive 0% while revenue growth was a negative 54%.

Pluristem Therapeutics Inc’s PE and PEG Ratio

Forward PE
0
Trailing PE
0
PEG
0

Its diluted EPS in the last 12-months stands at $-1.602 per share while it has a forward price to earnings multiple of 0 and a PEG multiple of 0. A low price to earnings ratio can mean the stock is attractively valued while a high ratio suggests the stock may be overvalued.

The PEG on the other hand provides a broader view compared to the P/E ratio and gives greater insight into Pluristem Therapeutics Inc’s profitability.

Pluristem Therapeutics Inc stock is trading at a EV to sales ratio of 9322.3583 and a EV to EBITDA ratio of 0. Its price to sales ratio in the trailing 12-months stood at 8006.8133.

Pluristem Therapeutics Inc stock pays annual dividends of $None per share, indicating a yield of 0% and a payout ratio of 0%.

Balance sheet and cash flow metrics

Total Assets
$0.000 billion
Total Liabilities
$0.000 billion
Operating Cash Flow
$0.000 billion
Capital Expenditure
$0.000 billion
Dividend Payout Ratio
0%

Pluristem Therapeutics Inc ended 1970 with $0.000 billion in total assets and $131.2 billion in total liabilities. Its intangible assets were valued at $0.000 billion while shareholder equity stood at $0.000 billion.

Pluristem Therapeutics Inc ended 1970 with $0.000 billion in deferred long-term liabilities, $0.000 billion in other current liabilities, billion in common stock, $0.000 billion in retained earnings and $0.000 billion in goodwill. Its cash balance stood at $0.000 billion and cash and short-term investments were $0.000 billion. The company’s total short-term debt was $0.000 billion while long-term debt stood at $0.000 billion.

Pluristem Therapeutics Inc’s total current assets stands at $0.000 billion while long-term investments were $0.000 billion and short-term investments were $0.000 million. Its net receivables were $0.000 billion compared to accounts payable of $0.000 billion and inventory worth $0.000 billion.

In 1970, Pluristem Therapeutics Inc's operating cash flow was $0.000 billion while its capital expenditure stood at $0.000 billion.

Comparatively, Pluristem Therapeutics Inc paid $0 billion in dividends in 1970.

Other key metrics

Current Trading Price
$0
52-Week High
$13.29
52-Week Low
$2.82
Analyst Target Price
$16.1

Pluristem Therapeutics Inc stock is currently trading at $0 per share. It touched a 52-week high of $13.29 and a 52-week low of $13.29. Analysts tracking the stock have a 12-month average target price of $16.1.

Its 50-day moving average was $0 and 200-day moving average was $0 The short ratio stood at 2.69 indicating a short percent outstanding of 5%.

Around 1215.1% of the company’s stock are held by insiders while 766.9% are held by institutions.

Frequently Asked Questions About Pluristem Therapeutics Inc

The stock symbol (also called stock or share ticker) of Pluristem Therapeutics Inc is PSTI

The IPO of Pluristem Therapeutics Inc took place on 2003-06-30

Similar Industry Stocks (Biotechnology)

Last Price
Chg
Chg%
$18.44
0
0%
$178.75
0
0%
$2.27
0
0%

Most Active

Last Price
Chg
Chg%
$58.63
-1.03
-1.73%
$92.12
-4.67
-4.82%
$5.12
-0.61
-10.65%
Apple Inc (AAPL)
$145.03
-5.62
-3.73%
$0.06
0.01
+12.74%

Top Gainers

Last Price
Chg
Chg%
$73
42.7
+140.92%
Oi S.A (OIBR-C)
$0
0
+100%
$0.02
0.01
+100%
$0.25
0.1
+66.44%
$2.85
1.01
+54.86%

Top Losers

Last Price
Chg
Chg%
$5.36
-22.58
-80.82%
$0.02
-0.06
-78.67%
Air T, Inc (AIRTW)
$0.01
-0.03
-75%
$4.51
-5.17
-53.41%
$11.5
-12.2
-51.48%

About

Pluristem Therapeutics Inc., together with its subsidiary, Pluristem Ltd., operates as a bio-therapeutics company in Israel. It focuses on the research, development, clinical trial, and manufacture of cell therapeutic products and related technologies for the treatment of various ischemic, inflammatory, and hematologic conditions, as well as autoimmune disorders. The company develops placental expanded (PLX) based cell therapy products, including PLX-PAD cells, which is Phase III clinical trial for the treatment of critical limb ischemia (CLI) in patients unsuitable for revascularization, recovery after surgery for hip fracture, and acute radiation syndrome (ARS), as well as peripheral and cardiovascular, and orthopedic diseases. It also develops PLX-R18 cells that is in Phase I clinical trial for incomplete hematopoietic recovery following hematopoietic cell transplantation, as well as conducts various animal studies for the evaluation of PLX-R18 for the treatment of ARS. The company has a license and commercialization agreement for conducting clinical trials and commercialization of its PLX-PAD product in South Korea related to the treatment CLI and intermittent claudication; and nTRACK, a collaborative project with Leitat to examine gold nano particles labeling of stem cells. It also has collaboration agreements with the NASA’s Ames Research Center to evaluate the potential of PLX cell therapies in preventing and treating medical conditions caused during space missions; and BIH Center for Regenerative Therapy and Berlin Center for Advanced Therapies to expand its framework and research agreement, as well as conduct a joint project evaluating the therapeutic effects of the registrant’s patented PLX cell product candidates for treatment of the respiratory and inflammatory complications associated with the COVID-19 coronavirus. Pluristem Therapeutics Inc. was founded in 2001 and is based in Haifa, Israel.

Address

Building No. 5, Haifa, Israel, 31905